Background
==========

HLA-B\*7 supertype alleles are common among people of African descent and are associated with viral control. In particular, HLA-B\*81 has been previously associated with reduced viral fitness. We analyzed the immunodominance of CD8+ T cell responses targeted by the B\*7 supertype alleles, viral evolution and fitness dynamics over 1yr in acutely infected patients.

Methods
=======

Six HLA-B\*7 supertype participants \[HLA-B\*81 (n=2), HLA-B\*4201 (n=3) and HLA-B\*4202 (n=1)\] identified with acute HIV-1 infection (antibody negative, vRNA positive) in KwaZulu-Natal, South Africa were studied. CD8+ T cell responses were measured by the IFN-γ ELIspot assay. Replication capacities of viruses encoding Gag-protease were measured. Full-length HIV-1 Gag clonal sequencing of plasma was performed at \~14 days post infection and 1yr later.

Results
=======

The average viral set point of the 4 HLA-B\*42 individuals was higher than the 2 HLA-B\*81, 4.89 vs 4.16 respectively. Approximately 28 days after viral infection, CD8+ T cell responses were directed to an average of 2/5 (range 2-4) HLA-B\*42 Gag-specific epitopes, median magnitude of 490 (range 170--2,480 SFC/million PBMCs). None of these 4 individuals had selected for escape mutations in the immunodominant TL9 epitope at 1yr post-infection. Interestingly, CD8+ T cell responses were only against the TL9 epitope for the 2 HLA-B\*81 patients with a median magnitude of 950 (range 300--1780 SFC/million PBMCs). One patient had a single wild type epitope in the transmitted virus, compared to 4/5 wild type epitopes in the second patient. However, CD8+ T cell responses were only elicited at the TL9 epitope with a low magnitude against T186S in the 1 patient with a much lower viral fitness.

Conclusion
==========

Strong, rather than broad immunodominant responses in HLA-B\*7 individuals is desirable in viral control. Furthermore, this study emphasizes the advantage of early dominant CD8+ T cell immune responses and an attenuated virus in conferring clinical benefit among HLA-B\*7 supertype individuals.
